Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 8Mesothelioma, Malignant 1Hot Flashes 1Endometrial Neoplasms 1Breast Cancer Patients Treated With T-DXd 1

Interventions

pembrolizumab 2Cyclophosphamide 2Cisplatin 2sargramostim 1regorafenib 1fludarabine 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1abemaciclib 1Surgical Procedures, Operative 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Platinum 1Pemetrexed 1Paclitaxel 1Nivolumab 1Midazolam 1Microarray Analysis 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Interferon-gamma 1Interferon-alpha 1Immunoenzyme Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Megestrol Acetate × Breast × Clear all
NCT00002465 2013-11-06

High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Unknown
BreastGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡